CAEL-101

Drug Profile

CAEL-101

Alternative Names: 11-1F4; CAEL101; Ch mAb 11-1F4; Chimeric fibril reactive monoclonal antibody 11-1F4 -Caelum Biosciences

Latest Information Update: 14 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Columbia University
  • Developer Caelum Biosciences; Columbia University; National Cancer Institute (USA)
  • Class Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloidosis; Amyloid light-chain amyloidosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Amyloid light-chain amyloidosis

Most Recent Events

  • 11 Dec 2017 CAEL-101 is available for licensing as of 11 Dec 2017. http://www.caelumbio.com/
  • 11 Dec 2017 Adverse events and efficacy data from a phase Ia/Ib trial in amyloid light chain amyloidosis presented at the 59th American Society of Hematology Annual Meeting (ASH-2017)
  • 11 Dec 2017 Caelum Biosciences plans a phase IIb/III trial for amyloid light chain amyloidosis in the second half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top